We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

kindr currently serves patients in the United States only. Content is for informational purposes elsewhere.

Menopause Data Hub

Menopause affects an estimated 1.2 billion women globally by 2030. It is the most common hormonal transition in women's life yet remains one of the most underdiagnosed and undertreated conditions worldwide. This page compiles continuously updated statistics on prevalence, symptoms, treatment, and research across 30+ countries.

Data updated continuously via PubMed + ClinicalTrials + FDA · Last updated: Jul 27, 2026, 6:00 AM
1.2B
women in menopause globally by 2030
51
average age of natural menopause onset
<10%
of eligible women receive hormone therapy
3-6 months
average wait for a menopause specialist in the US
Kindr Health. (2026). Menopause Statistics and Global Data Hub. kindr.health/menopause-statistics

All statistics on this page are freely citable under Creative Commons CC BY 4.0. No permission required.

Global PrevalenceSymptoms andHormone TherapyLong-term HealthGLP-1 MedicationsBrain &Musculoskeletal &ResearchTrials

Global Prevalence

Globalverified 2026-06-16
1.2B
women will be in menopause worldwide by 2030
The most common hormonal transition in women's life.
Globalverified 2026-06-16
47M
women enter menopause each year worldwide
Globalverified 2026-06-16
51 years
average age of natural menopause
Typical range 45–55 years.
Globalverified 2026-06-16
~1%
of women experience premature menopause (under 40)
Source: ESHRE, 2023
Globalverified 2026-06-16
~15%
of menopause cases globally are surgical
United Statesverified 2026-06-16
6,000
women reach menopause every day in the US
United Statesverified 2026-06-16
50M+
women currently in menopause or perimenopause
United Kingdomverified 2026-06-16
13M
women currently peri- or post-menopausal in the UK
Indiaverified 2026-06-16
103M
postmenopausal women in India (estimated)
Japanverified 2026-06-16
50.5 years
average age of menopause in Japan
Lower than the global average; possibly linked to BMI and smoking differences.
Australiaverified 2026-06-16
3.9M
Australian women in menopause or perimenopause

Symptoms and Quality of Life

Globalverified 2026-06-16
75%
of women experience hot flashes
Source: NAMS, 2023
Globalverified 2026-06-16
60%
report chronic sleep disruption
Globalverified 2026-06-16
44%
report significant brain fog or memory changes
Globalverified 2026-06-16
30%
experience depression symptoms during the menopause transition
Globalverified 2026-06-16
38%
report meaningful impact on work performance
Globalverified 2026-06-16
73%
of women do not seek medical treatment for menopause symptoms
United Kingdomverified 2026-06-16
60%
of women say menopause negatively affected their work
Australiaverified 2026-06-16
45%
report reduced quality of life due to menopause symptoms
United Statesverified 2026-06-16
7.4 years
average duration of hot flash symptoms
Globalverified 2026-06-16
1 in 3
of women experience menopause symptoms for more than 10 years

Hormone Therapy and the Treatment Gap

United Statesverified 2026-06-16
<10%
of eligible women receive hormone therapy
Despite guidelines supporting its use.
United Statesverified 2026-06-16
3–6 months
average wait for a menopause specialist
United Statesverified 2026-06-16
<4 hours
of menopause training in the average US medical school curriculum
Source: NAMS, 2022
United Statesverified 2026-06-16
-79%
HRT use fell after the 2002 WHI study and never fully recovered
Despite the study's findings being substantially revised.
Source: NEJM, 2017
United Kingdomverified 2026-06-16
+37%
rise in HRT prescriptions 2019–2022
Following updated NICE guidelines.
Europeverified 2026-06-16
5%–35%
range of HRT use across EU member states
A 7x gap between Spain (lowest) and Finland (highest).
Source: EMAS, 2023
Australiaverified 2026-06-16
+25%
rise in HRT use after the 2020 AMS guideline update
United Kingdomverified 2026-06-16
52%
of perimenopausal women not receiving any GP support
Globalverified 2026-06-16
+340%
rise in telehealth menopause consultations 2020–2023
United Statesverified 2026-06-16
$1.8B
annual US economic cost of menopause-related lost productivity

Long-term Health Outcomes

Globalverified 2026-06-16
30%
of skin collagen lost in the first 5 years post-menopause
Globalverified 2026-06-16
2–3%
annual bone density loss in the first 5 years post-menopause
Globalverified 2026-06-16
2x
cardiovascular disease risk within 10 years of menopause onset
Globalverified 2026-06-16
2x
Alzheimer's disease is more common in women than men
Menopause is a proposed biological risk factor.
United Statesverified 2026-06-16
1 in 2
US women over 50 who will experience an osteoporosis fracture
Globalverified 2026-06-16
up to -48%
cardiovascular risk reduction with HRT started within 10 years of menopause

GLP-1 Medications and Menopause Weight Management

United Statesverified 2026-06-16
Menopausal US women
fastest-growing GLP-1 prescription demographic in 2024–2025
Source: IQVIA, 2025
Globalverified 2026-06-16
5–8 lbs
average weight gain attributable to menopause
30% of women gain 15+ lbs.
Globalverified 2026-06-16
up to 30%
of GLP-1 weight loss that can come from lean muscle
Globalverified 2026-06-16
1 in 3
of GLP-1 users plateau within 6 months
Globalverified 2026-06-16
~15%
semaglutide average weight loss at 68 weeks (STEP 1)
Globalverified 2026-06-16
~22%
tirzepatide average weight loss at 72 weeks (SURMOUNT-1)
Globalverified 2026-06-16
up to 24.2%
retatrutide weight loss at 48 weeks (Phase 2)
Globalverified 2026-06-16
up to +40%
additional lean muscle preserved when combining GLP-1 with resistance training

Brain & Cognition

Menopause is increasingly understood as a neurological transition. This section tracks the emerging science on menopause, cognition, and long-term brain health — including where the research is settled and where it is still evolving. The role of hormone therapy in cognitive outcomes and dementia prevention remains an area of active investigation and is not settled science.

Globalverified 2026-07-07
2 in 3
Alzheimer's patients are women
Nearly two-thirds of all Alzheimer's disease cases occur in women — a disparity researchers increasingly attribute to biological and hormonal factors, not longevity alone.
Globalverified 2026-07-07
60%+
of Alzheimer's patients are postmenopausal women
Postmenopausal women make up more than 60% of all people living with Alzheimer's disease.
Globalverified 2026-07-07
A neurological transition
Menopause symptoms are largely neurological
Many menopause symptoms — including brain fog, memory changes, sleep disruption, and mood shifts — are neurological in nature, reflecting estrogen's role in brain function. Research describes the menopause transition as a critical neurological window in women's health.
Globalverified 2026-07-07
A critical window
for cognitive health intervention
Research suggests the menopause transition may be an optimal window for supporting long-term brain health, as estrogen-regulated systems shift during this period. The role of hormone therapy in cognitive outcomes remains an area of active scientific research and debate.
Globalverified 2026-07-07
Women's brain health
a major, long-underserved frontier in health research
Women's brain health is emerging as a major frontier in health investment and research, reflecting how underserved the intersection of menopause and cognitive health has been. Specific market-size estimates remain preliminary and vary by source.

Musculoskeletal & Joint Health

Menopause affects connective tissue, joints, and muscle. This section tracks emerging science on musculoskeletal conditions that peak during the perimenopausal window — including adhesive capsulitis (frozen shoulder), which recently entered mainstream conversation. Evidence is best described as associative and emerging, not settled cause.

Globalverified 2026-07-07
Ages 40–60
Frozen shoulder peak years overlap perimenopause
Frozen shoulder (adhesive capsulitis) is most prevalent between ages 40 and 60 — the same window as perimenopause and menopause — and is 2–4x more common in women than men, prompting researchers to investigate a hormonal link.
Globalverified 2026-07-07
Estrogen-linked
Declining estrogen may affect joint & connective tissue
Estrogen supports collagen structure, joint lubrication, and inflammation regulation. Its decline during menopause may contribute to joint stiffness and conditions like frozen shoulder, though the exact mechanism remains under active investigation.

Latest Published Research

Updated via PubMed
View all recent studies on PubMed →

Active Clinical Trials

Updated via ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: Jul 27, 2026, 6:00 AM.

For journalists and researchers.

Can I cite these statistics freely?

Yes. All statistics on this page are freely citable under Creative Commons CC BY 4.0. No permission is required. Citation format: kindr Health. (2026). Menopause Statistics and Global Data Hub. kindr.health/menopause-statistics

How often is this data updated?

Research feeds (PubMed, clinical trials, FDA) refresh automatically every 24 hours. Core statistics are verified and updated quarterly by kindr's editorial team, or immediately when a major study is published.

What sources does kindr use?

All statistics are sourced from peer-reviewed journals, government databases (CDC, ONS, NHS), and recognized medical societies (NAMS, BMS, IMS, WHO). Every statistic includes a source citation and year. We do not use industry-funded data without disclosure.

Is this a global resource?

Yes. We cover menopause data from the US, UK, EU, Australia, India, Japan, Canada, and global estimates where available. Use the region filter to view data specific to your audience.

Can I request specific statistics?

If there is a specific data point relevant to your article that is not on this page, contact press@kindr.health and we will research it and add it to the hub.

Who maintains this page?

This page is maintained by kindr Health's editorial team and reviewed by Kindr Health Clinical Team. All statistics link to original sources.

Reviewed by Kindr Health Clinical Team · NPI 1609792902 · Reviewed June 2026 · Updated July 2026

Editorial note: Statistics are verified against primary sources. Data showing ranges reflects variation across studies or populations. Kindr Health does not alter or selectively report statistics to support commercial interests.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026

Press and media enquiries
press@kindr.health

For permission-free citation, see the CC BY 4.0 note above. For interviews and commentary, see kindr.health/press.

The kindr Menopause Briefing

A short weekly briefing for journalists and researchers: one new statistic, one clinical trial update, and expert context — straight from our data hub. No marketing, just data.

For journalists, researchers, and clinicians.

Journalists: cite our data freely →
About Kindr Health: kindr provides physician-supervised menopause and hormonal health care via telehealth in all 50 US states → kindr.health
Ask Dot